The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000986370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
28/07/2026
Date registered
Help: Date registered
12/08/2026
Date last updated
Help: Date last updated
12/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 1 Safety and Pharmacology Study of Oral GBP-088 in Healthy Adults
Scientific title
A Phase 1 Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral GBP-088 in Healthy Participants
Additional trial identifiers [1] 318030 0
GBP-088-101
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Kidney stone disease 343037 0
Condition category
Condition code
Renal and Urogenital 339134 339134 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Approximately 8 healthy men or women will be enrolled in the food effect part of this study (Cohort SC-6).

In Cohort SC-6 the participants will only receive GBP-088. There will be no participants receiving placebo. Cohort SC-6 receives a single dose of GBP-088 twice. The first dose will be following an overnight fast of at least 10 hours. The second dose will be given after a 4 day washout and following a standard high fat and high calorie meal. The meal will contain about 1000 calories with approximately 150 protein calories, 250 carbohydrate calories and 600 fat calories. Participants will be required to refrain from fluids for an hour before dosing and an hour after each dosing. The dose to be used in SC-6 will not be any higher than previously tested single doses and will not exceed 2000mg.
Intervention code [1] 334905 0
Treatment: Drugs
Description of the comparator or control
Oral GBP-088 given under fasted conditions will be considered the control group.
Control group
Active

Outcomes
Primary outcome [1] 346373 0
Assess the composite safety and tolerability of single doses of GBP-088 in healthy adult participants.
Timepoint [1] 346373 0
Treatment-emergent adverse events will be collected from the time of signing the informed consent form through the final visit which is Day 12 post dose for Cohort SC-6 . Physical examinations in Cohort SC-6 will be conducted at screening, Day -1 and Day 12 post dose. Symptom-directed physical examinations will be conducted if clinically indicated. Clinical laboratory assessments of blood and urine in Cohort SC-6 will be collected at screening, Day -1, Day 1, Day 2, Day 5, Day 6 and Day 12 post dose. ECGs in Cohort SC-6 will be collected at screening, Day -1, Day 1 predose and at 2, 4 and 8 hours after dosing, Day 2, Day 5 predose and at 2, 4 and 8 hours after dosing, Day 6 and Day 12 post dose. Vital signs in Cohort SC-6 will be collected at screening, on Day -1, on Day 1 predose and at 1, 2, 4, 8 and 12 hours after dosing, on Day 2 at 24 hours post dose, on Day 3, on Day 5 predose and at 1, 2, 4, 8 and 12 hours after dosing, on Day 6 at 24 hours post dose, on Day 7 and on Day 12 post dose.
Secondary outcome [1] 465559 0
Plasma concentrations of GBP-088 after a single oral dose of GBP-088
Timepoint [1] 465559 0
In Cohort SC-6 blood will be collected for PK analyses on Day 1 pre-dose and then at 15, 30, 45, 60 and 90 minutes, and 2, 4, 6, 8, and 12 hours post dose. A 24-hour and a 36-hour post dosing sample will be collected on Day 2, a 48-hour post dosing sample will be collected on Day 3. Samples will be collected on Day 5 pre-dose and then at 15, 30, 45, 60 and 90 minutes, and 2, 4, 6, 8, and 12 hours post dose. A 24-hour and a 36-hour post dosing sample will be collected on Day 6, a 48-hour post dosing sample will be collected on Day 7.
Secondary outcome [2] 465560 0
Urine concentrations of GBP-088 after single oral doses of GBP-088
Timepoint [2] 465560 0
In Cohort SC-6 all urine voids will be collected for PK analyses on Day 1 and Day 5 pre-dose and then within the following windows; 0-3 hours, 3-6 hours, 6-9 hours, 9-12 hours, 12-18 hours, 18-24 hours, 24-30 hours, 30-36 hours, 36-42 hours, 42-48 hours post dose.

Eligibility
Key inclusion criteria
Deemed healthy as determined by medical history, physical examination, vital sign measurements, ECG, and laboratory safety tests
Not lactating or pregnant
Body weight at least 50kg (male) and 45kg (female) and body mass index within the range 18-32 kg/m2 (inclusive)
Capable of giving signed informed consent
Agrees to be available for all study visits and cooperates fully with the requirements of the study protocol, including the schedule of assessments
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Past or current history of moderate or severe psychiatric illness
Past or current history of mild, moderate, or severe substance abuse
Past or current history of alcohol use disorder
History of acute illness, infectious condition or chronic disease within 14 days before Screening
Any history of cardiovascular, cerebrovascular, or peripheral vascular disease
Use or intended use of prohibitied medications
Received treatment with another investigational drug, investigational device, or approved therapy for investigational use within 30 days or 5 half-lives (whichever is longer) before Screening
Positive alcohol breath test or urine test for drugs of abuse
Positive serology panel
Clinically significant vital signs
Clinically significant laboratory abnormalities
Clinically significant history or presence of ECG findings

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
central randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated simple randomisation sequence
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment postcode(s) [1] 46277 0
2031 - Randwick

Funding & Sponsors
Funding source category [1] 322581 0
Commercial sector/Industry
Name [1] 322581 0
GondolaBio Australia Pty Ltd
Country [1] 322581 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
GondolaBio Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325508 0
None
Name [1] 325508 0
Address [1] 325508 0
Country [1] 325508 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321055 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 321055 0
Ethics committee country [1] 321055 0
Australia
Date submitted for ethics approval [1] 321055 0
01/07/2026
Approval date [1] 321055 0
29/07/2026
Ethics approval number [1] 321055 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152510 0
Dr Christopher Argent
Address 152510 0
Scientia Clinical Research Ltd. Levels 5 and 6, Bright Building, Corner High and Avoca Sts., Randwick, NSW 2031
Country 152510 0
Australia
Phone 152510 0
+61 02 9382 5844
Fax 152510 0
Email 152510 0
Contact person for public queries
Name 152511 0
Puja Motwani
Address 152511 0
Scientia Clinical Research Ltd. Levels 5 and 6, Bright Building, Corner High and Avoca Sts., Randwick, NSW 2031
Country 152511 0
Australia
Phone 152511 0
+61 2 9382 5820
Fax 152511 0
Email 152511 0
Contact person for scientific queries
Name 152512 0
Puja Motwani
Address 152512 0
Scientia Clinical Research Ltd. Levels 5 and 6, Bright Building, Corner High and Avoca Sts., Randwick, NSW 2031
Country 152512 0
Australia
Phone 152512 0
+61 2 9382 5820
Fax 152512 0
Email 152512 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Only aggregate participant data will be available from this study



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.